

COMPLIANCE WITH CORPORATE GOVERNANCE REQUIREMENTS

Date: September 04, 2026

To,

Listing Operation Department, BSE Limited, 20th Floor, P.J.Towers, Dalal Street, Mumbai – 400 001	National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 Maharashtra
--	---

(Turnaround Corporate Advisors Private Limited is referred to as the "**Book Running Lead Manager**" or the "**BRLM**")

Subject: Proposed initial public offering of equity shares of face value of ₹ 10 each (the "Equity Shares") of Iberia Pharmaceuticals India Limited (Formerly known as Iberia Pharmaceuticals India Private Limited and prior to that Satnam Medical Agencies Private Limited) (the "Company") through a Fresh Issue of the Equity Shares (the "Issue")

Dear Sir/Madam,

With reference to captioned subject, we confirm the following is true, fair, correct, accurate, not misleading and without omission of any matter that is likely to mislead and is adequate to enable investors to make a well-informed decision.

We confirm that the Company is in compliance with the requirements relating to corporate governance under the Companies Act, 2013, as amended, and rules made thereunder, (the "**Companies Act**"), *inter alia*, in relation to appointment of independent directors, composition of the Board, constitution of the committees of the Board including the audit committee, the stakeholders' relationship committee, the nomination and remuneration committee, and the corporate social responsibility committee.

The Company is in compliance with the Companies Act and with the requirements relating to corporate governance under Chapter II, Chapter IV and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "**SEBI Listing Regulations**"), *inter alia*, in relation to the composition of the board of directors of the Company ("**Board**"), constitution of the board committees, including the constitution of the audit committee, stakeholder relationship committee and nomination and remuneration committee, corporate social responsibility committee and formulation of various policies and also undertakes to comply with all such provisions of the SEBI Listing Regulations as and when such provisions becomes applicable to the Company.

Details of composition of the Board and the committees are as disclosed in **Annexure A**. Status of our compliance with requirements of Chapter IV of the SEBI Listing Regulations is provided in tabular format in **Annexure B** and **Annexure C**. Further, disclosures with respect to the loans/ guarantees/comfort letters/ security provided by the Company, directly or indirectly to Promoter/ Promoter Group entities or any other entity controlled by them, as required pursuant to the SEBI circular

1

Reg. Add.: Property No. 4, Block-C, First Floor, Sector-8, Dwarka, Bagdola, South West Delhi, New Delhi, Delhi, India, 110077

Corp. Add.: Unit No. 304-305, 3rd Floor, Tower B, Global Business Park, M.G. Road, Near Guru Dronacharya Metro Station, Gurugram, Haryana, 122002, India

Email: info@iberiapharmaceuticals.com; **Phone:** +91-7428762354
Website: www.iberiapharmaceuticals.com

no. SEBI/HO/CFD/CMD-2/P/CIR/2021/567 dated May 31, 2021, are provided in Annexure C. The Company undertakes that the contents of the website of the Company are correct and that it shall update any change in the content of its website within two working days from the date of such change in content.

The details of the management organization structure and a chart indicating the same has been annexed hereto as **Annexure D**.

We confirm that the members of the Audit Committee noted that pursuant to the Securities Exchange Board of India (Issue of Capital and Disclosure Requirements) (Fourth Amendment) Regulations, 2022, published in the Official Gazette on November 23, 2022, the Audit Committee is required to approve the key performance indicators ("KPIs") disclosed in the draft red herring prospectus to be filed with the Securities and Exchange Board of India ("SEBI"), BSE Limited and National Stock Exchange of India Limited (collectively, the "Stock Exchanges"), in respect of the proposed initial public offering of equity shares of face value of ₹ 10/- each ("Equity Shares") of the Company and confirm that verified and audited details for all the KPIs disclosed to the investors and promoters at any point of time during the three years period preceding the date of the filing of the Draft Red Herring Prospectus ("DRHP") to be submitted by the Company with the Securities and Exchange Board of India ("SEBI") are disclosed in the "Basis for Issue Price" section of the DRHP and will be disclosed in the "Basis for Issue Price" section of the RHP and Prospectus to be filed with the Registrar of Companies, Delhi ("ROC") and further confirms that the details for all such KPIs disclosed under "Basis for Issue Price" section have been verified and audited in accordance with applicable laws and auditing procedures.

The Audit Committee also confirmed that KPIs disclosed under "Basis for Issue Price" section of the DRHP have been verified and audited, in accordance with applicable laws and auditing procedures, including the SEBI (Issue of Capital and Disclosure Requirements), Regulations, 2018 and SEBI circular (SEBI/HO/CFD/CFD-PoD-2/P/CIR/2025/28) dated February 28, 2025 and NSE Circular (NSE/CML/2025/08) dated February 28, 2025 that inter alia prescribe certain KPI data and collection parameters. The members of the Audit Committee also noted that no other KPIs pertaining to the Company other than those disclosed in the "Basis for Issue Price" section of the DRHP and annexed as Annexure A, have been disclosed to earlier investors of the Company during the three years period preceding the date of filing of the DRHP / no KPIs pertaining to the Company have been disclosed to earlier investors of the Company at any point of time during the three years prior to filing of the DRHP of the Company

We confirm that the information in this certificate, including any annexures hereto, is true and correct and there is no untrue statement or omission of any matter, which would render the contents of this certificate misleading in its form or context.

We confirm that this certificate, including any annexures hereto, is for informational purpose and for inclusion (in part or full) in the DRHP, the RHP and the Prospectus filed in relation to the Issue (collectively, the "Issue Documents") or any other Issue-related material, and may be relied upon by the Company, the BRLM and the Legal Counsel appointed by the Company, in relation to the Issue.

We hereby consent to the submission of this certificate as may be necessary to the SEBI, the Registrar of Companies, Delhi, the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE"), [BSE and NSE together are referred to as the "Stock Exchanges"] and any other regulatory authority and/or for the records to be maintained by the BRLM and in accordance with applicable law. We confirm that we will immediately communicate any changes in writing in the above information to

2

Reg. Add.: Property No. 4, Block-C, First Floor, Sector-8, Dwarka, Bagdola, South West Delhi, New Delhi, Delhi, India, 110077

Corp. Add.: Unit No. 304-305, 3rd Floor, Tower B, Global Business Park, M.G. Road, Near Guru Dronacharya Metro Station, Gurugram, Haryana, 122002, India

Email: info@iberiapharmaceuticals.com; **Phone:** +91-7428762354
Website: www.iberiapharmaceuticals.com



IBERIA PHARMACEUTICALS INDIA LIMITED
(Erstwhile "IBERIA PHARMACEUTICALS INDIA PRIVATE LIMITED")
U21002DL2013PLC250040

the BRLM until the date when the Equity Shares are listed and commence trading on the Stock Exchanges pursuant to the Issue. In the absence of any such communication from us, the BRLM and the Legal Counsel can assume that there is no change to the above information until the date when the Equity Shares are listed and commence trading on the Stock Exchanges pursuant to the Issue.

All capitalized terms not defined herein would have the same meaning as attributed to it in the Issue Documents.

Sincerely,

For and behalf of **Iberia Pharmaceuticals India Limited**

(Formerly known as Iberia Pharmaceuticals India Private Limited and prior to that Satnam Medical Agencies Private Limited)


Raj Kumar
Company Secretary and Compliance Officer
M. No: A- 36310



Place: Gurugram

ANNEXURE A

I. Composition of Board of Directors

Sl. No.	Name of the Director	PAN & DIN	Category (Chairperson / Executive / Non-Executive / Independent Director / Nominee) &	Initial Date of Appointment	Date of Re-Appointment	Date of Cessation	Tenure*	Date of Birth	No. of directorship in listed entities including this listed entity [in reference to Regulation 17A(1) and Regulation 25 of the SEBI Listing Regulations]	No. of Independent Directorship in listed entities including this listed entity [in reference to proviso to regulation 17A(1) of the SEBI Listing Regulations]	Number of memberships in Audit/ Stakeholder Committee(s) including this entity (Refer Regulation 26(1) of the SEBI Listing Regulations)	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of the SEBI Listing Regulations)
Mr.	Nitin Jain	PAN: ADWPJ9790P & DIN: 5276862	Managing Director	March 30, 2013	March 01, 2025	-	-	October 31, 1976	1	-	-	-
Mr.	Rishabh Jain	PAN: AMOPJ0710C & DIN: 5276845	Whole Time Director	May 02, 2021	March 01, 2025	-	-	July 29, 1990	1	-	-	-
Mr.	Saurav Ojha	PAN: AAOP06545L & DIN: 8104529	Whole Time Director	September 30, 2023	March 01, 2025	-	-	October 09, 1986	1	-	-	-
Mr.	Atul Bhola	PAN: AHFPB1773K & DIN: 08730166	Independent Director	March 01, 2025	-	-	-	October 27, 1979	1	1	2	1

I. Composition of Board of Directors

Title Mr./ Ms)	Name of Director	PAN & DIN	Category (Chairperson /Executive/ Non- Executive/ independ ent & Nominee)	Initial Date of Re- Appointment	Date of Resignation	Tenure*	Date of Birth	No. of directorship in listed entities including this listed entity	No. of Independent Directors hip in listed entities including this listed entity	Number of memberships in Audit/ Stakeholder Committee(s)	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of the SEBI Listing Regulations)
Ms.	Harmeet Kaur	PAN-AHHPK0273A DIN: 01737331	Independent Director	March 01, 2025	-	-	February 27, 1979	1	1	1	1
Ms.	Preeti Jain	PAN: AMPPJ6327A & DIN: 08803345	Independent Director	January 21, 2026	-	-	September 28, 1987	3	3	4	-

Whether Regular chairperson appointed

Whether Chairperson is related to managing director or CEO

*PAN of any director would not be displayed on the website of Stock Exchange

& Category of directors means executive/non-executive/independent/Nominee. if a director fits into more than one category write all categories separating them with hyphen
to be filled only for Independent Director. Tenure would mean total period from which Independent director is serving on Board of directors of the listed entity in continuity without any cooling off period.

II. Composition of Committees						
Name of Committee	Whether Regular chairperson appointed	Name of Committee members	Category (Chairperson/ Executive/ Non-Executive/ independent/ Nominee)&	Date of Appointment	Date of cessation	
Audit Committee	Yes	Atul Bhola	Chairperson, Independent Director	February 24, 2026	NA	
		Preeti Jain	Member, Independent Director	February 24, 2026	NA	
		Nitin Jain	Member, Managing Director	February 24, 2026	NA	
Nomination & Remuneration Committee	Yes	Atul Bhola	Chairperson, Independent Director	February 24, 2026	NA	
		Harmeet Kaur	Member, Independent Director	February 24, 2026	NA	
		Preeti Jain	Member, Independent Director	February 24, 2026	NA	
Corporate Social Responsibility Committee	Yes	Nitin Jain	Chairperson, Managing Director	September 05 th , 2024	NA	
		Saurav Ojha	Member, Whole-Time Director	September 05 th , 2024	NA	
		Rishabh Jain	Member, Whole-Time Director	September 05 th , 2024	NA	

II. Composition of Committees

Name of Committee	Whether Regular chairperson appointed	Name of Committee members	Category (Chairperson/ Executive/ Non-Executive/ independent/ Nominee)*	Date of Appointment	Date of cessation
Stakeholders Relationship Committee'		Atul Bhola	Member, Independent Director	February 24, 2026	NA
	Yes	Harmeet Kaur	Chairperson, Independent Director	January 30, 2026	NA
		Nitin Jain	Member, Managing Director	January 30, 2026	NA
		Atul Bhola	Member, Independent Director	January 30, 2026	NA
IPO Committee	Yes	Nitin Jain	Chairperson, Managing Director	July 21, 2026	NA
		Saurav Ojha	Member, Whole-Time Director	July 21, 2026	NA
		Rishabh Jain	Member, Whole-Time Director	July 21, 2026	NA
		Atul Bhola	Member, Independent Director	July 21, 2026	NA

II. Composition of committees					
<i>Name of Committee</i>	<i>Whether Regular chairperson appointed</i>	<i>Name of Committee members</i>	<i>Category (Chairperson/Executive/Non-Executive/Independent/Nominee)</i>	<i>Date of Appointment</i>	<i>Date of Cessation</i>
Audit Committee	Yes	Atul Bhola	Chairperson (Independent Director)	30.01.2026	NA
Audit Committee	Yes	Preeti Jain	Member (Independent Director)	30.01.2026	NA
Audit Committee	Yes	Nitin Jain	Member (Managing Director)	30.01.2026	NA
Nomination & Remuneration Committee	Yes	Atul Bhola,	Chairperson (Independent Director)	30.01.2026	NA
Nomination & Remuneration Committee	Yes	, Harmeet Kaur	Member (Independent Director)	30.01.2026	NA
Nomination & Remuneration Committee	Yes	Preeti Jain	Member (Independent Director)	30.01.2026	NA
Stakeholders Relationship Committee	Yes	Harmeet Kaur,	Chairperson (Independent Director)	30.01.2026	NA
Stakeholders Relationship Committee	Yes	Nitin Jain,	Member (Managing Director)	30.01.2026	NA
Stakeholders Relationship Committee	Yes	Preeti Jain	Member (Independent Director)	30.01.2026	NA
Corporate Social Responsibility Committee	Yes	Nitin Jain, ,	Chairperson (Managing Director)	05/09/2024	NA
Corporate Social Responsibility Committee	Yes	Saurav Ojha	Member (Whole-Time Director)	05/09/2024	NA
Corporate Social Responsibility Committee	Yes	Rishabh Jain	Member (Whole-Time Director)	05/09/2024	NA
Corporate Social Responsibility Committee	Yes	Atul Bhola	Member (Independent Director)	24/02/2026	NA

III. Meeting of Board of Directors				
<i>Date(s) of Meeting (if any) in the previous quarter</i>	<i>Date(s) of Meeting (if any) in the relevant quarter</i>	<i>Whether requirement of quorum met in the relevant quarter</i>	<i>Maximum gap between any two consecutive (in no. of days)</i>	<i>Number of independent directors present in the relevant quarter</i>

Reg. Add.: Property No. 4, Block-C, First Floor, Sector-8, Dwarka, Bagdola, South West Delhi, New Delhi, India, 110077
Corp. Add.: Unit No. 304-305, 3rd Floor, Tower B, Global Business Park, M.G. Road, Near Guru Dronacharya Metro Station, Gurugram, Haryana, 122002, India
Email: info@iberiapharmaceuticals.com; **Phone:** +91-7428762354
 Website: www.iberiapharmaceuticals.com

III. Meeting of Board of Directors

12/01/2026	14/04/2026	Yes	-	3	6
21/01/2026	18/04/2026	Yes	-	3	6
30/01/2026	07/06/2026	Yes	-	2	5
24/02/2026	10/06/2026	Yes	-	3	6
02/03/2026	-	Yes			

IV. Meetings of Committees

Names of committees	Date(s) of meeting of the committee in the relevant quarter	Whether requirement of Quorum met (details)*	Number of Directors present*	Number of independent directors present*	Date(s) of meeting of the committee in the previous quarter	Maximum gap between any two consecutive meetings in number of days*
Audit Committee -	07/06/2026	Yes	5	2	02/03/2026	-
Nomination & Remuneration Committee	-	Yes	-	-	30/01/2026	-
Corporate Social Responsibility Committee	-	Yes	-	-	30/01/2026	-
Stakeholders Relationship Committee	-	Yes	-	-	30/01/2026	-

V. Related Party Transactions	Subject	Compliance status (Yes/No/NA) <i>refer note below</i>
Whether prior approval of audit committee obtained		Yes
Whether shareholder approval obtained for material Related Party Transaction		NA
Whether details of Related Party Transaction entered into pursuant to omnibus approval have been reviewed by the Audit Committee		NA
Whether a policy has been formulated on materiality of and dealing with related party transactions		Yes
Whether such approval of audit committee was omnibus approval in terms of Regulation 23(3) of the SEBI Listing Regulations		NA
Note:		
1 In the column "Compliance Status", compliance or non-compliance may be indicated by Yes/No/NA. For example, if the Board has been composed in accordance with the requirements of Listing Regulations, "Yes" may be indicated. Similarly, in case the Listed Entity has no related party transactions, the words "N.A." may be indicated.		
2 If status is "No" details of non-compliance may be given here.		

VI. Affirmations
1. The composition of Board of Directors is in terms of the SEBI Listing Regulations,
2. The composition of the following committees is in terms of the SEBI Listing Regulations,
a. Audit Committee
b. Nomination & Remuneration Committee
c. Corporate Social Responsibility Committee
d. Stakeholders Relationship Committee
e. IPO Committee

VI. Affirmations

3. The committee members have been made aware of their powers, role and responsibilities as specified in the SEBI Listing Regulations,
4. The meetings of the board of directors and the above committees have been conducted in the manner as specified in the SEBI Listing Regulations, and Companies Act, 2013.
5. The corporate governance compliance report and/or the corporate governance compliance report submitted in the previous quarter has been placed before Board of Directors. Any comments/observations/advice of the board of directors may be mentioned here.
6. The Company has approved a Material Subsidiary Policy and has complied with the Corporate Governance requirements with respect to Subsidiary.
7. The Company has formulated a committee of independent directors to recommend that the price band is justified based on quantitative factors / key performance indicators vis-à-vis the weighted average cost of acquisition of primary issuance / secondary transaction(s).

ANNEXURE B

Status of compliance with Chapter IV of the SEBI Listing Regulations		
Disclosure on website in terms of the SEBI Listing Regulations		
	Item	Compliance status (Yes/No/NA)
	Details of business	Yes
	Terms and conditions of appointment of independent directors	Yes
	Composition of various committees of board of directors	Yes
	Code of conduct of board of directors and senior management personnel	Yes
	Details of establishment of vigil mechanism/ Whistle Blower policy	Yes
	Criteria of making payments to non-executive directors	Yes
	Policy on dealing with related party transactions	Yes
	Policy for determining "material" subsidiaries	Yes
	Details of familiarization programmes imparted to independent directors	Yes
	Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances	Yes
	Email address for grievance redressal and other relevant details	Yes
	Financial results	Yes
	Shareholding pattern	Yes
	Details of agreements entered into with the media companies and/or their associates	N.A
	New name and the old name of the listed entity	Yes

Reg. Add.: Property No. 4, Block-C, First Floor, Sector-8, Dwarka, Bagdola, South West Delhi, New Delhi, India, 110077
Corp. Add.: Unit No. 304-305, 3rd Floor, Tower B, Global Business Park, M.G. Road, Near Guru Dronacharya Metro Station, Gurugram, Haryana, 122002, India
Email: info@iberiapharmaceuticals.com; **Phone:** +91-7428762354
 Website: www.iberiapharmaceuticals.com

Disclosure on website in terms of "The SEBI Listing Regulations"		Compliance status (Yes/No/NA) refer note below
As per Regulation 46(2) of the SEBI Listing Regulations:		
a) Details of business		Yes
b) Terms and conditions of appointment of independent directors		Yes
c) Composition of various committees of board of directors		Yes
d) Code of conduct of board of directors and senior management personnel		Yes
e) Details of establishment of vigil mechanism/Whistle Blower policy		Yes
f) Criteria of making payments to non-executive directors, if the same has not been disclosed in annual report		Yes
g) Policy on dealing with related party transactions		Yes
h) Policy for determining 'material' subsidiaries		Yes
i) Details of familiarization programmes imparted to independent directors		Yes
j) Email address for grievance redressal and other relevant details		Yes
k) Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances		Yes
l) Financial information		Yes
m) Shareholding pattern		Yes
n) Details of agreements entered into with the media companies and/or their associates		Yes
o) Schedule of analyst or institutional investor meet, and presentations made by the listed entity to analysts or institutional investors simultaneously with submission to stock exchange		NA
p) New name and the old name of the listed entity		Yes

Disclosure on website in terms of "The SEBI Listing Regulations"	
Item	Compliance status (Yes/No/NA) refer note below
q) Advertisements as per Regulation 47(1)	NA
r) Credit rating or revision in credit rating obtained by the entity for all its outstanding instruments	NA
s) Separate audited financial statements of each subsidiary of the listed entity in respect of a relevant financial year	Yes
As per SEBI Listing Regulations:	
a) Whether company has provided information under separate section on its website as per Regulation 46(2)	Yes
b) Materiality Policy as per Regulation 30	Yes
c) Dividend Distribution policy as per Regulation 43A (as applicable)	Yes
<i>It is certified that these contents on the website of the listed entity are correct.</i>	

Annual Affirmations		
Particulars	Regulation Number	Compliance status (Yes/No/NA) refer note below
Independent director(s) have been appointed in terms of specified criteria of 'independence' and / or 'eligibility'	16(1)(b) & 25(6)	Yes
Board composition	17(1), 17(1) (c), 17(1A) & 17(1B)	Yes
Meeting of board of directors	17(2)	Yes
Quorum of board meeting	17(2A)	Yes
Review of Compliance Reports	17(3)	NA

Annual Affirmations		
Particulars	Regulation Number	Compliance status (Yes/No/NA) refer note below
Plans for orderly succession for appointments	17(4)	Yes
Code of Conduct	17(5)	Yes
Fees/compensation	17(6)	Yes
Minimum Information	17(7)	Yes
Compliance Certificate	17(8)	Yes
Risk Assessment & Management	17(9)	Yes
Performance Evaluation of Independent Directors	17(10)	Yes
Recommendation of board	17(11)	Yes
Maximum number of directorships and tenure	17A	Yes
Composition of Audit Committee	18(1)	Yes
Meeting of Audit Committee	18(2)	Yes
Composition of Nomination & Remuneration Committee	19(1) & (2)	Yes
Quorum of Nomination and Remuneration Committee meeting	19(2A)	Yes
Meeting of Nomination & Remuneration Committee	19(3A)	Yes
Composition of Stakeholder Relationship Committee	20(1),20(2) and 20(2A)	Yes
Meeting of Stakeholder Relationship Committee	20 (3A)	Yes
Composition and role of Risk Management Committee	21(1), (2), (3), (4)	NA
Meeting of Risk Management Committee	21(3A)	NA
Quorum of Risk Management Committee meeting		NA

Reg. Add.: Property No. 4, Block-C, First Floor, Sector-8, Dwarka, Bagdola, South West Delhi, New Delhi, India, 110077
Corp. Add.: Unit No. 304-305, 3rd Floor, Tower B, Global Business Park, M.G. Road, Near Guru Dronacharya Metro Station, Gurugram, Haryana, 122002, India
Email: info@iberiapharmaceuticals.com; **Phone:** +91-7428762354
 Website: www.iberiapharmaceuticals.com

Annual Affirmations		
Particulars	Regulation Number	Compliance status (Yes/No/NA) refer note below
Vigil Mechanism	22	Yes
Policy for related party Transaction	23(1), (1A), (5), (6), (7) & (8)	Yes
Prior or Omnibus approval of Audit Committee for all related party transactions	23(2), (3)	Yes
Approval for material related party transactions	23(4)	Yes
Disclosure of related party transactions on consolidated basis	23(9)	Yes
Composition of Board of Directors of unlisted material subsidiaries	24(1)	NA
Other Corporate Governance requirements with respect to subsidiaries of listed entity	24(2), (3), (4), (5) & (6)	NA
Annual Secretarial Compliance Report	24(A)	NA
Alternate Director to Independent Director	25(1)	NA
Maximum Tenure of independent directors	25(2)	Yes
Meeting of independent directors	25(3) & (4)	Yes
Familiarization of independent directors	25(7)	Yes
Declaration from Independent Director	25(8) & (9)	Yes
Directors and Officers insurance	25(10)	NA
Memberships in Committees	26(1)	Yes
Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel	26(3)	Yes
Disclosure of Shareholding by Non- Executive Directors	26(4)	NA
Policy with respect to Obligations of directors and senior management	26(2) & 26(5)	Yes

Annual Affirmations		
Particulars	Regulation Number	Compliance status (Yes/No/NA) refer note below
Obligation of employees to not enter into any agreement with regard to compensation or profit sharing in connection with dealings in securities of listed entity without prior approval	26(6)	Yes
<i>Note</i> In the column "Compliance Status", compliance or non-compliance may be indicated by Yes/No/N.A. For example, if the Board has been composed in accordance with the requirements of Listing Regulations, "Yes" may be indicated. Similarly, in case the Listed Entity has no related party transactions, the words "N.A." may be indicated. If status is "No" details of non-compliance may be given here. If the Listed Entity would like to provide any other information the same may be indicated here.		
III Affirmations:		
The Listed Entity has approved the Material Subsidiaries Policy and the Corporate Governance requirements with respect to the subsidiaries of Listed Entity have been complied.		

ANNEXURE C

Affirmations	Broad heading	Regulation Number	Compliance status (Yes/No/NA) refer note below
	Copy of the annual report including balance sheet, profit and loss account, directors report, corporate governance report, business responsibility report displayed on website	46(2)	Yes
	Presence of Chairperson of Audit Committee at the Annual General Meeting	18(1)(d)	Yes
	Presence of Chairperson of the nomination and remuneration committee at the annual general meeting	19(3)	Yes
	Presence of Chairperson of the Stakeholder Relationship committee at the annual general meeting	20(3)	NA
	Whether "Corporate Governance Report" disclosed in Annual Report	34(3) read with para C of Schedule V	NA
Note <i>1 In the column "Compliance Status", compliance or non-compliance may be indicated by Yes/No/NA. For example, if the Board has been composed in accordance with the requirements of Listing Regulations, "Yes" may be indicated. Similarly, in case the Listed Entity has no related party transactions, the words "N.A." may be indicated.</i> <i>2 If status is "No" details of non-compliance may be given here.</i> <i>3 If the Listed Entity would like to provide any other information the same may be indicated here.</i>			

I. Disclosure of Loans / guarantees / comfort letters / securities etc

(A) Any loan or any other form of debt advanced by the listed entity directly or indirectly to:

Entity	Aggregate amount advanced during six months	Balance outstanding at the end of six months
Promoter or any other entity controlled by them	Nil	Nil
Promoter Group or any other entity controlled by them	Nil	Nil

Directors (including relatives) or any other entity controlled by them	<i>Nil</i>	<i>Nil</i>
KMPs or any other entity controlled by them	<i>Nil</i>	<i>Nil</i>

(B) Any guarantee/ comfort letter (by whatever name called) provided by the listed entity directly or indirectly, in connection with any loan(s) or any other form of debt availed by:

Entity	Type (guarantee, comfort letter etc.)	Aggregate amount of issuance during six months	Balance outstanding at the end of six months (taking into account any invocation)
Promoter or any other entity controlled by them	<i>Nil</i>	<i>Nil</i>	<i>Nil</i>
Promoter Group or any other entity controlled by them	<i>Nil</i>	<i>Nil</i>	<i>Nil</i>
Directors (including relatives) or any other entity controlled by them	<i>Nil</i>	<i>Nil</i>	<i>Nil</i>
KMPs or any other entity controlled by them	<i>Nil</i>	<i>Nil</i>	<i>Nil</i>

C) Any security provided by the listed entity directly or indirectly, in connection with any loan(s) or any other form of debt availed by:

Entity	Type of security (cash, shares etc.)	Aggregate value of security provided during six months	Balance outstanding at the end of six months
Promoter or any other entity controlled by them	<i>Nil</i>	<i>Nil</i>	<i>Nil</i>
Promoter Group or any other entity controlled by them	<i>Nil</i>	<i>Nil</i>	<i>Nil</i>

Directors (including relatives) or any other entity controlled by them	Nil	Nil	Nil
KMPs or any other entity controlled by them	Nil	Nil	Nil

II. Affirmations:

All loans (or other form of debt), guarantees, comfort letters (by whatever name called) or securities in connection with any loan(s) (or other form of debt) given directly or indirectly by the listed entity to promoter(s), promoter group, director(s) (including their relatives), key managerial personnel (including their relatives) or any entity controlled by them are in the economic interest of the company.

Annexure D

